Amgen, maker of the brand-name pegfilgrastim (Neulasta), and Mylan, which partnered with Biocon to develop a biosimilar (Fulphila), have entered a joint status report in the District Court for the Western District of Pennsylvania.
Amgen, maker of the brand-name pegfilgrastim (Neulasta), and Mylan, which partnered with Biocon to develop a biosimilar (Fulphila), have entered a joint status report in the District Court for the Western District of Pennsylvania. In the status report, they agree that Amgen cannot maintain a claim of infringement against Mylan with respect to US Patent Number 8,273,707, which covers a process for purifying proteins by mixing a protein preparation with a solution involving 2 salts.
This latest development stems from an earlier decision in another case related to the same patent; in March 2018, a Delaware court dismissed a lawsuit brought by Amgen over a different biosimilar developer’s alleged infringement of this same patent; in that case, Amgen alleged that Coherus BioSciences infringed on its patent because Coherus’ biosimilar pegfilgrastim, later approved as Udenyca, mixed salts that, in combinations, were equivalent to Amgen’s patented combinations. According to the court, Amgen had previously acknowledged that Coherus did not literally infringe on the patent.
Later, in July 2019, the federal circuit affirmed that decision, saying that Amgen “clearly and unmistakably surrendered salt combinations other than the particular combinations recited in the claims.”
In this month’s joint status report in the case concerning Fulphila, the parties write that, in light of the court’s precedential decision in Amgen v Coherus BioSiences, Agmen and Mylan agree that Amgen can no longer maintain its claim related to this patent.
The stipulation has no impact on the claims of another patent—US Patent Number 9,643,997—that Amgen alleges Mylan has infringed. This patent covers processes for purifying proteins expressed in nonmammalian systems.
Mylan, however, requested that the court extend a stay on discovery related to the latter patent for an additional 30 days. Last month, another biosimilar developer, Sandoz, filed a response to Amgen’s petition for a rehearing of Amgen v Sandoz, a case in which the federal circuit sided with Sandoz related to alleged infringement of the patent. In light of the pending decision in that matter, the court agreed to stay further action in this case pending further order of the court.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.